Psychiatric Drug Shortages Strain Patients and Doctors in Austria
- Persistent shortages of psychotropic medications are placing severe strain on patients and doctors across Austria, with pharmaceutical wholesalers reporting that 74,000 medicine packs go missing from supply chains...
- The supply crunch centers heavily on the antipsychotic medication quetiapine, particularly in its retard formulation where the active ingredient is released gradually to maintain an even blood level.
- Similar challenges are documented by Gerald Klug, a psychiatrist and chairman of pro mente Austria, the Austrian umbrella association for mental and social health.
Persistent shortages of psychotropic medications are placing severe strain on patients and doctors across Austria, with pharmaceutical wholesalers reporting that 74,000 medicine packs go missing from supply chains daily. According to Monika Vögele of the Austrian association of pharmaceutical full-line wholesalers, Phago, the overall supply situation is not good, driven in part by the stockpiling of neuroleptics and chronic delivery failures for specific antipsychotics.
Delivery Disruptions Target Retarded Quetiapine
The supply crunch centers heavily on the antipsychotic medication quetiapine, particularly in its retard formulation where the active ingredient is released gradually to maintain an even blood level. Gerald Grundschober, medical director of the specialized clinic for psychiatric rehabilitation in Hollenburg, Lower Austria, treats up to 30 percent of his patients with quetiapine. Quetiapine is used widely to treat conditions including depression and anxiety disorders. According to Grundschober, shortages of the extended-release formula force patients to switch to non-retarded versions, which require altering intake schedules and can trigger additional psychological stress. Many patients hesitate for a long time before starting medication therapy due to fears of potential side effects, meaning that any forced medication change creates renewed anxiety and risks causing therapy dropouts.
Vulnerable Patients Face Added Hurdles
Similar challenges are documented by Gerald Klug, a psychiatrist and chairman of pro mente Austria, the Austrian umbrella association for mental and social health. Klug explains that mentally strained individuals often lack the strength to visit multiple pharmacies searching for available stock. To ease short-term pressures, Klug advocates for better information sharing between hospital pharmacies and the outpatient sector. Hospital facilities frequently hold stock that is unavailable in the outpatient sector, leaving discharged patients unable to continue the medication with which they started their therapy in institutional care.
Manufacturing Delays Push Availability Dates Back
The Federal Office for Safety in Health Care lists numerous psychotropic medications as unavailable or restricted in its distribution restriction register. While the Austrian Dachverband der Sozialversicherungsträger reported an easing of overall medication shortages in mid-July and noted that four out of five cases permit switching to an equivalent active ingredient, psychiatrists warn that psychotropic drugs carry unique risks. Klug notes that even identical active ingredients can cause different side effects due to distinct manufacturing processes and chemical embeddings. In an inquiry response sent to Grundschober in mid-July, the Federal Office for Safety in Health Care initially pointed to an estimated delivery date between late July and early October for extended-release quetiapine. Current registry entries now push expected delivery dates out to mid-October or March 2027, citing manufacturing delays that leave both physicians and patients facing a lack of planning security.
